<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Pharmaceutical Management]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[实施新修订药品生产质量管理规范过程中药品技术转让研究相关要求浅析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[刘军田,冯巧巧,谢纪珍,李泮海]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘军田,冯巧巧,谢纪珍,李泮海</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504018&flag=1]]></guid><cfi:id>87</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[对医药科技政策实施效果的DEA评估及研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[王虹,冯国忠]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王虹,冯国忠</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501016&flag=1]]></guid><cfi:id>86</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Introduction of the guideline on clinical development of fixed combination medicinal products issued by EMA]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The European Medicines Agency (EMA) has recently issued an industry guidance on clinical development of fixed combination medicinal products in March 2017. This guideline addresses the considerations and clinical development requirements of fixed combination medicinal products.As there is no guidance regarding this kind of products in China currently,we hope to provide some reference for the research, development and review of fixed combination medicinal products in China by introducing this guidance.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHOU Yu, REN Manru and GONG Xinjiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Yu, REN Manru and GONG Xinjiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809015&flag=1]]></guid><cfi:id>85</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discuss on the common problems of drug technology transfer in Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper analyzed the common problems in drug technology transfer,such as proof document, research of prescription and technology,quality comparison,comparative study on the stability and so on, based on relevant regulatory documents,completed work of drug technology transfer in sShandong Province and daily evalution experiences.In order to reduce the risks in the transfer process and ensure the quality consistency of the technology transfering products ,we give some suggestions on how to avoid related problems in the drug technology transfer.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XIE Jizhen, ZHOU Chong, YIN Ningning, LIU Juntian and JIANG Xiaofei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Jizhen, ZHOU Chong, YIN Ningning, LIU Juntian and JIANG Xiaofei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809016&flag=1]]></guid><cfi:id>84</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The relationship analysis of sampling inspection and fast inspection in technological regulation for drug market]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the reform direction of  the technology regulatory system and mechanism  for  drug market, and protect the safe and effective of drug.<b>Methods</b>  The drug sampling inspection and fast inspection work since 2006 was analyzed, and to discriminate  the feasibility of the drug sampling inspection and fast inspection work functions merge.<b>Results  and Conclusion</b>  The drug sampling inspection and fast inspection work functions merge was an effective way to land the fast inspection techniques. For deporting the substandard medicines out of the market, in addition to improve detection capability, more should adjust technical supervision system and mechanism.]]></description>
<pubDate>2019/1/14 14:42:23</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Jun, JIANG Guangling and ZHANG Zhonghu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jun, JIANG Guangling and ZHANG Zhonghu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812016&flag=1]]></guid><cfi:id>83</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of requirements between Chinese and American pharmacopoeia for related substances in hemodialysis concentrate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Hemodialysis is an effective way to treat patients with acute and chronic renal failure.As a part of hemodialysis，the quality of hemodialysis concentrate has an important impact on the safty and effectiveness of dialysis. In this paper, the requirements of some related substances in hemodialysis concentrates in Chinese and American Pharmacopoeia were compared for reference by professionals in pharmacopoeia formulation and related fields.]]></description>
<pubDate>2018/10/18 9:58:39</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[YE Chenghong, YANG Yuxi and KE Linnan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Chenghong, YANG Yuxi and KE Linnan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810015&flag=1]]></guid><cfi:id>82</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of on-site inspection of cosmetics production license]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analysis the problems existing in the implementation of Specification for the licensing of cosmetics production in Shandong cosmetics production enterprises, provide technical reference for the formulation of personalized regulatory measures and the implementation of standardized implementation in the future.<b>Methods</b>  The defective items which were found in the on-site inspection of 111 factory-times were collected in order to analyze the main and common problems and causes of quality system in the cosmetics manufacturing enterprises,and to put forward the corresponding suggestion.<b>Results and Conclusion</b>  The enterprises should improve their sense of self-discipline,gradual establish a perfect quality management system, attach importance to the management of materiel and details,ensure the pertinence and effectiveness of training，and improve employee executive ability.]]></description>
<pubDate>2018/10/18 9:58:39</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[WANG Minghui, SUN Miao, CHEN Hongzhong, TANG Zian, HU Xiaotong, XIN Ming and LIU Xiuqi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Minghui, SUN Miao, CHEN Hongzhong, TANG Zian, HU Xiaotong, XIN Ming and LIU Xiuqi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810016&flag=1]]></guid><cfi:id>81</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2018年山东省药品生产和GMP认证许可分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:17</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[张杰,韩莹]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张杰,韩莹</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909011&flag=1]]></guid><cfi:id>80</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于应急检验的文献查新与检索方法案例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:17</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[周维利,赵艳霞,公为红]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>周维利,赵艳霞,公为红</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909012&flag=1]]></guid><cfi:id>79</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Data analysis of administrative licensing cosmetics certain inspection institution from 2012 to 2017]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To understand the quality of imported cosmetics and cosmetics for special purposes that are applied to be marketed in China.<b>Methods</b>  The cosmetics which needed government review and approval from 2012 to 2017 were tested and the test data was analyzed statistically.<b>Results</b>  The imported cosmetics were mainly from Korea and Japan.Domestic cosmetics for special purpose were mainly from Hainan and Guangdong.The unqualified items were mainly toxicological tests (multi-skin) and microbial indicators (total number of colonies, sum of mold and yeast).The unqualified cosmetics were mainly non-special purpose cosmetics imported from South Korea and the United States.<b>Conclusion</b>  It is necessary to strengthen the statistical analysis of the results of administrative licensing inspection so as to find out the regular and universal problems and adjust the evaluation content.The study also showed that the on-site verification of imported cosmetics production enterprises should be increased to ensure the safety cosmetics use.]]></description>
<pubDate>2019/8/30 17:59:13</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SUN Jing, GUO Haixia, JIANG Jun and CHENG Chunlei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Jing, GUO Haixia, JIANG Jun and CHENG Chunlei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908014&flag=1]]></guid><cfi:id>78</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative analysis of four municipalities directly under the central government and Zhejiang Province based on biomedical patents]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Based on the statistics of biomedical patent data,analysis of the number of patent applications,the composition of patent types, the composition of patent applicants,and the distribution of patent IPC classification numbers in Zhejiang Province,and through the comparative analysis with Beijing,Shanghai,Tianjin,Chongqing biomedical patents,Then analyze and explain the results to determine the status of Zhejiang biomedical patents. The results show that, the number of patent applications in Zhejiang and four municipalities has increased year by year, the type of invention patent,the applicant of the enterprise is dominant,Patent applications are concentrated on the A61,C07,and C12 classification numbers.Zhejiang Province needs to further develop its location advantage, strengthen government guidance,industry-university-research cooperation，to promote innovation and development in the field of biomedicine.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[CHENG Jiahui, DONG Zuojun and SUN Guojun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Jiahui, DONG Zuojun and SUN Guojun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907014&flag=1]]></guid><cfi:id>77</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Introduction of EU notified body and enlightenment to vaccine supervision in China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a special preventive biological product, vaccine is widely used in disease prevention and control. However, the frequent occurrence of vaccine safety incidents in recent years has aroused widespread concern among the public. This article introduces Notified Body in the European Union, and discusses the vaccine regulatory system and problems in China. Finally, it is recommended to introduce third-party institutional supervision measures in the field of vaccine safety supervision.]]></description>
<pubDate>2019/6/27 10:49:44</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[YAN Bobo, DONG Zuojun and SUN Guojun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Bobo, DONG Zuojun and SUN Guojun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906015&flag=1]]></guid><cfi:id>76</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The present situation and contruction of information development in food and drug inspection--take Shandong Institute for Food and Drug Control as an example]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper summarizes the overall construction of informatization in three years, including the construction of computer room, network and all kinds of application systems. It focuses on the construction of LIMS, experiences and lessons to provide reference for the information construction of inspection and detection units.]]></description>
<pubDate>2019/3/29 12:07:30</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[HA Lingling, ZHANG Zhonghu, JIANG Guangling, HU Nan and SUI Baochun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HA Lingling, ZHANG Zhonghu, JIANG Guangling, HU Nan and SUI Baochun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902015&flag=1]]></guid><cfi:id>75</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Data analysis based on LIMS system in the era of big data]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the gradual establishment and improvement of food and drug inspection information platform and business system, a large number of rich data resources have accumulated. This puts new demands on the laboratory information management system (LIMS) function——big data mining and statistics. This paper discussed the application of big data in LIMS of food and drug inspection.Through big data, we can analyze and extract valuable information that cannot be extracted by small data, and serve the development of the inspection business.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[JIANG Jun, HU Nan, SUI Baochun and HA Lingling]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Jun, HU Nan, SUI Baochun and HA Lingling</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901016&flag=1]]></guid><cfi:id>74</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[安徽省2018年中药饮片GMP认证检查缺陷分析及建议]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[钱利武,金斌]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>钱利武,金斌</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912014&flag=1]]></guid><cfi:id>73</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Common problems and analysis of evaluation of traditional Chinese medicine preparations in Shandong medical institutions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  This paper summarized and analysed the problems found in the evaluation of traditional Chinese medicine preparations in medical institutions of our province, and explores the reference for our province's "record management of traditional Chinese medicine preparations prepared by medical institutions using traditional techniques" under the new situation of encouraging the development of traditional Chinese medicine and ensuring the safety of drug use by the public.<b>Methods</b>  The review of Chinese medicine preparations submitted for approval in our province from 2015 to 2018 was investigated,and the main problems in the application data of Chinese medicine preparations in medical institutions were summarized and analyzed.<b>Results</b>  The declaration data of preparations in medical institutions need to be improved in terms of name, function, instruction, process and quality standards, and clinical research data.<b>Conclusion</b>  It is suggested that the relevant medical institutions should strengthen the scientific and necessary examination of the previous topics, do a good job in relevant research work, fully consider the actual needs of hospitals and patients, so as to promote the healthy development of traditional Chinese medicine preparations in medical institutions and prosper the cause of traditional Chinese medicine.]]></description>
<pubDate>2019/12/2 15:14:04</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[YIN Ningning, XIE Jizhen, ZHOU Liming, ZHOU Yong and LIU Juntian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YIN Ningning, XIE Jizhen, ZHOU Liming, ZHOU Yong and LIU Juntian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911015&flag=1]]></guid><cfi:id>72</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the orphan drug approvals of FDA in 2019]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper analyzed statistic all of  the new drug approved by FDA in 2019. Emphasizing on analyzing the difference of the basic information, priority for approval, clinical number of orphan drugs and new drugs, to understand the priority for orphan drug approvals. Some suggestions are put forward on the orphan drug policy in China，providing references for the establishment of orphan drug policies and research in our country．]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHOU Chong, LIU Juntian, XIAO Jie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Chong, LIU Juntian, XIAO Jie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009013&flag=1]]></guid><cfi:id>71</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Patent overview of PI3Kδ inhibitors for the treatment of cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[PI3Kδ is an important subtype of PI3K kinases, which is mainly expressed in leukocytes and plays an important role in the proliferation, differentiation, maturation and self-reaction of B cells. It is an effective target in the treatment of hematological malignancies and autoimmune diseases such as rheumatoid arthritis. Based on the patent application literatures dating 2015—2019 related to PI3Kδ inhibitors, this paper analyzes its structural types in patents, providing supports for related researchers.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[WAN Yue and LI Meng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WAN Yue and LI Meng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007015&flag=1]]></guid><cfi:id>70</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The application of new classification method of cosmetics in the analysis of administrative license inspection results]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To understand the role of the stratified classification method in the analysis of cosmetic test results.<b>Methods</b>  According to the “cosmetics classification standard”, the administrative license inspection cosmetics entrusted by enterprises from 2012 to 2017 were stratified and classified, and the inspection results of different categories of cosmetics were analyzed.<b>Results</b>  Nourishing and cream dosage form products were the most submitted for inspection. Repair function and oil agent products showed the highest unqualified rate. Cream dosage form and moisturizing function products showed the most unqualified batch. The microbial unqualified products were most water agent. The toxicology unqualified products were most the oil agent and the cream emulsion agent.<b>Conclusion</b>  The new stratified classification method is more conducive to tracing the safety risk points of cosmetics. In the process of cosmetics supervision, it can guide the key points of supervision and the formulation of supervision and inspection items according to risk differences of unqualified cosmetics by different dosage forms, functional claims, application sites and applicable people.]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SUN Jing<sup>1</sup> and FANG Xueqiang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Jing<sup>1</sup> and FANG Xueqiang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004012&flag=1]]></guid><cfi:id>69</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[“数字药监”改革背景下食品药品检验机构数字化转型的探索及思考]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[李樱红,周霖,徐涛,倪维芳]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李樱红,周霖,徐涛,倪维芳</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003014&flag=1]]></guid><cfi:id>68</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于LIMS系统电子签章应用的探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:11</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[胡楠,刘毅,隋宝春,姜俊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡楠,刘毅,隋宝春,姜俊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002015&flag=1]]></guid><cfi:id>67</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[问答式审评体系在药品技术转让评价的应用探索]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:27</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[王晓英,陈佩毅,许庆锐,王爽,张一凡,林焕冰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王晓英,陈佩毅,许庆锐,王爽,张一凡,林焕冰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001013&flag=1]]></guid><cfi:id>66</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the influence of the mode of centralized volume-based drug purchase]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202012012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The centralized drug purchase is an important way to solve the problem of high drug prices in the process of  China’s medical reform. Through constant exploration,drug bidding and purchase ushered in the era of centralized volume-based purchase nationwide. By the research method of consulting literature and current events,this paper summarized the impact of the new mode of drug bidding and purchase on production enterprises circulation enterprises,medical institutions and patients. At the same time, this paper explored measures for all parties to better cope with negative effects, and to create a good industrial environment.]]></description>
<pubDate>2021/1/12 9:35:54</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[HAN Zhongjiang, XU Qian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Zhongjiang, XU Qian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202012012&flag=1]]></guid><cfi:id>65</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[福建省中药产业科技创新发展及对策研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/9/9 11:28:13</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[林津晶，徐伟，林羽]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>林津晶，徐伟，林羽</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202108015&flag=1]]></guid><cfi:id>64</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application analysis of scientific supervision based on big data of drug detection LIMS system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[After cloud computing, Internet of things and mobile Internet, big data has become a research hotspot in the information and Internet industry. In the field of drug testing, data sources, types and so on are complex, data analysis is a very important aspect. LIMS system has a large number of basic data in all aspects of inspection and detection, which requires effective big data processing technology to analyze and process these massive data. Starting from the concept, technology and basic framework of big data analysis, this paper studies the application of big data analysis technology, especially in the field of drug inspection and detection, so as to provide effective decision support for the leadership to implement scientific supervision and risk early warning, and prospects the development prospect and future application of big data analysis.]]></description>
<pubDate>2021/8/16 15:40:10</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[HU Nan, LIU Yi, ZOU Zhiyong, SUN Tong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Nan, LIU Yi, ZOU Zhiyong, SUN Tong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107015&flag=1]]></guid><cfi:id>63</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[TLC-SERS技术体系构建及应用研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:20</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[胡楠，刘毅，谢强胜，张中湖]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡楠，刘毅，谢强胜，张中湖</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106017&flag=1]]></guid><cfi:id>62</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Taking lessons from the past,abiding by academic ethics and good academic style of scientific research]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  At present, the requirement of universities for master and doctoral dissertations is to pass the plagiarism detection system. Since some academic misconducts in the academic circles especially in the biomedical fields were exposed, the academic community, including universities and scientific research institutes related to the medicines, has strictly controlled academic standards, allowing the repetition rate of papers to drop and then lowering, and we have proposed higher academic standards. Requirements, spur the academic community to correct academic behavior, adhere to research integrity, and abide by academic ethics strictly.<b>Methods</b>  This article summarizes the past academic misconducts in and abroad, explores the root causes of academic misconduct, and tries to find measures to correctly guide and regulate academic ethics.<b>Results</b>  The series of solutions proposed in the article are expected to provide some ideas and solutions for scientific research management departments especially in the medical fields.<b>Conclusions</b>  Scholars are the reserve force of knowledge groups and the country. To engage in academic activities, one should engage in scientific research based on the principle of trust and honesty, and ought to be a veritable academic researcher.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Ye, LU Jie, SHENG Fengnian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Ye, LU Jie, SHENG Fengnian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102015&flag=1]]></guid><cfi:id>61</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on the current situation and improvement of TCM preparation quality standard in Shandong Province medical institutions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To standardize the quality standards of TCM preparations in medical institutions of Shandong Province and ensure the safety, effectiveness and quality control of TCM preparation in medical institutions.<b>Methods</b>  Based on the status of TCM preparation quality standards of medical institutions in Shandong Province, this paper summarizes the existing problems of TCM preparation quality standards of medical institutions in Shandong Province by sorting out and summarizing Shandong Provincial Medical Institution Preparation Specification(volume 1, first edition) and the improved varieties.<b>Results</b>  The quality standard items of 780 varieties collected in Shandong Provincial Medical Institution Preparation Specification (Volume I, first edition) are relatively simple, and the quality control index is single, comparing the quality standards of 310 varieties in the standard improvement task before and after the improvement, the overall standard control was significantly improved. In the future work, we should strengthen the quality standard of security, integrity and applicability, and improve the quality of preparations to ensure the safe and effective clinical application.<b>Conclusion</b>  As the legal standard of Shandong Provincial medical institution preparation, medical institution preparation standard in Shandong Province will be greatly improved after the promulgation and implementation of Shandong Provincial Medical Institution Preparation Specification.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XU Xingyan<sup>1,2</sup>, XU Lili<sup>1,2</sup>, YU Yameng<sup>1</sup>, LIN Lin<sup>1</sup>, WANG Bing<sup>1</sup>, LIU Chuanmin<sup>3</sup>, LIN Yongqiang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Xingyan<sup>1,2</sup>, XU Lili<sup>1,2</sup>, YU Yameng<sup>1</sup>, LIN Lin<sup>1</sup>, WANG Bing<sup>1</sup>, LIU Chuanmin<sup>3</sup>, LIN Yongqiang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102016&flag=1]]></guid><cfi:id>60</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Problems and suggestions on quality management of the production enterprises of Chinese herbal pieces]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the defects that found in GMP compliance inspection of Chinese herbal pieces and explore the problems of quality management, in order to provide reference for ensuring product quality. <b>Methods</b>  The defects in the GMP compliance inspection of 82 Chinese herbal pieces production enterprises in 2020 were taken as the research object, and the defects were analyzed by the method of analysis and induction. <b>Results and Conciusion</b>  The proportion of serious defects found in the quality management of Chinese herbal pieces production enterprises is the highest. Chinese herbal pieces production enterprises should firmly establish the sense of quality responsibility, carry out targeted improvement measures, effectively improve the quality management level, and ensure that the quality of Chinese herbal pieces meets the requirements of medication.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LIU Xiaoqiong<sup>1,2</sup>, QIAN Liwu<sup>1</sup>, XUE Zhenglian<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Xiaoqiong<sup>1,2</sup>, QIAN Liwu<sup>1</sup>, XUE Zhenglian<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110014&flag=1]]></guid><cfi:id>59</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Construction and analysis of effectiveness evaluation system for “running at most once” reform in food and drug inspection institutes based on data envelopment analysis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to scientifically evaluate the “running at most once” reform effectiveness in food and drug inspection institutions, a dual comprehensive reform effectiveness evaluation model of “public satisfaction - speed up and quality improvement for inspection service” was proposed based on literature review and policy analysis. The evaluation system of public satisfaction was formed by 11 sub-indicators. The evaluation system of speed up and quality improvement for inspection service was formed by 4 sub-indicators. Effectiveness of “running at most once” reform was evaluated based on Matlab language and data envelopment analysis (DEA). Finally, the research suggestions of effectiveness evaluation for “run at most once” reform were proposed.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Yinghong, GONG Qing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yinghong, GONG Qing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110015&flag=1]]></guid><cfi:id>58</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the relevant requirements for the change of chemical drug registration standards under the new regulations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The drug registration standard is an important part of the drug registration certificate. By studying the current"Drug Registration Management Measures" and "Technical Guidelines for the Research on Pharmaceutical Changes of Listed Chemical Drugs (Trial)", this paper discusses and summarizes the basic requirements, reasons for change and research verification contents of the change of chemical drug registration standards under the new regulations, so as to provide reference for the normative change of chemical drug registration standards.]]></description>
<pubDate>2022/10/10 9:39:46</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LU Xueming, LIU Fulong, LI Debao, FANG Juanjuan, LIU Juntian, XIE Jizhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Xueming, LIU Fulong, LI Debao, FANG Juanjuan, LIU Juntian, XIE Jizhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209013&flag=1]]></guid><cfi:id>57</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Problems and suggestions found by registrants and record holders of cosmetics entrusted to produce in Shandong Province in 2021]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[After the promulgation and implementation of the Regulations on the Supervision and Administration of Cosmetics, the concept of cosmetics registrant/record holder has been clarified. The important form for cosmetics registrant/record holder to organize cosmetics production is commissioned production.  Based on the inspection of cosmetics registrants/record holders carried out in our province as the data support, this paper makes a statistical analysis of the problems existing in the implementation of the system of cosmetics registrants/record holders entrusted to produce under the new background of the implementation of the Regulations, and puts forward suggestions on how to do a good job in risk control.]]></description>
<pubDate>2022/9/5 13:24:45</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[BAI Runchao, HE Yunya, WANG Minghui, LIU Xiuqi, WANG Rui, XUE Zhenxi, LIU Feiyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BAI Runchao, HE Yunya, WANG Minghui, LIU Xiuqi, WANG Rui, XUE Zhenxi, LIU Feiyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208013&flag=1]]></guid><cfi:id>56</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the problems of pharmaceutical retail chain enterprises in Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to prevent and control the operation quality and safety risks of pharmaceutical retail chain enterprises, this article uses the methods of literature reviews, questionnaires, expert interviews to analyze the current status and problems of the quality management of pharmaceutical retail chain enterprises in Shandong Province, and combined with the special rectification of the whole province to put forward rationalized and professional countermeasures and suggestions for pharmaceutical retail chain enterprises in Shandong Province.]]></description>
<pubDate>2022/7/19 16:37:42</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SHANG Jingying<sup>1</sup>, LIN Xiaoming<sup>1</sup>, WANG Qun<sup>1</sup>, ZHANG Ran<sup>2</sup>, BAI Jianxue<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHANG Jingying<sup>1</sup>, LIN Xiaoming<sup>1</sup>, WANG Qun<sup>1</sup>, ZHANG Ran<sup>2</sup>, BAI Jianxue<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206015&flag=1]]></guid><cfi:id>55</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Problems and suggestions in production quality management of microbial drug manufacturing enterprises]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper introduced the microbial drugs, summarizes and analyzed the defects and causes of microbial drugs in Anhui province in recent years. By combining the problems and particularity of microbial drugs in the production quality management, suggestions and opinions are put forward, which is helpful to improve the quality management level of microbial drugs.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LIU Xiaoqiong<sup>1,2</sup>, QIAN Liwu<sup>1</sup>, XUE Zhenglian<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Xiaoqiong<sup>1,2</sup>, QIAN Liwu<sup>1</sup>, XUE Zhenglian<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205015&flag=1]]></guid><cfi:id>54</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the integration of CNAS system and GMP and other quality systems in QC laboratories of pharmaceutical enterprises]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Implementing GMP management in QC laboratories of pharmaceutical enterprises is the requirement of drug management regulations. At the same time, the implementation of CNAS or ICH Q10 or ISO9001 can further improve the management level of laboratories. This paper compares the main characteristics of CNAS, GMP, ICH Q10 and ISO9001 systems, and expounds the position of QC laboratory in pharmaceutical enterprises and its relevance with relevant departments. When implementing multiple systems such as CNAS, GMP, ICH Q10 and ISO9001 at the same time, we must fully understand and grasp the requirements of each system, sort out the common and personalized requirements, take targeted measures, and adopt the strategy of relying on and complementing each other, Organically combine and integrate all systems.]]></description>
<pubDate>2022/6/8 14:30:17</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LIU Qun<sup>1</sup>, LYU Feng<sup>1</sup>, MU Wenjie<sup>1</sup>, XIE Qingyi<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Qun<sup>1</sup>, LYU Feng<sup>1</sup>, MU Wenjie<sup>1</sup>, XIE Qingyi<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205016&flag=1]]></guid><cfi:id>53</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Common problems and analysis of registration of traditional Chinese medicine preparations in Shandong medical institutions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyse and summarize the common registration problems of traditional Chinese hospital medicine preparation in Shandong province, and discuss the thought of gradual transformation from classic＆famous prescription toward new Chinese traditional medicine, so as to provide reference for the declaration.<b>Methods</b>  The situation of relevant policy announcements and preparation declarations in recent years were summarized, thence discuss the common problems of the review on traditional Chinese medicine preparations and analyze the reasons for them since the implementation of the Notice on the Registration Management Measures of the Hospital Medicine Preparations in Shandong Province.To analyze and summarize the common registration problems of traditional Chinese hospital medicine preparation in Shandong province, and discuss the thought of gradual transformation from classic＆famous prescription toward new Chinese traditional medicine, so as to provide reference for the declaration. Methods Summarize the situation of relevant policy announcements and preparation declarations in recent years, thence discuss the common problems of the review on traditional Chinese medicine preparations and analyze the reasons for them since the implementation of the Notice on the Registration Management Measures of the Hospital Medicine Preparations in Shandong Province.<b>Results</b>  Applicants should pay attention to the integrity of the application materials and related research, the scientific rationality of the topic, and the awareness of the exemption of materials. <b>Conclusion</b>  It is recommended to strengthen self-construction, attach importance to communication with competent authorities, and actively explore the cooperation mode of pharmaceutical research and development.]]></description>
<pubDate>2022/5/10 10:37:37</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[FANG Juanjuan, XIE Jizhen, LU Xueming, GAO Yanjia, WU Haijun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FANG Juanjuan, XIE Jizhen, LU Xueming, GAO Yanjia, WU Haijun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204016&flag=1]]></guid><cfi:id>52</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of drug management mode and current situation on Internet]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the current Internet drug business model and the status quo, for Industry Academic Research, Internet business supervision work to provide reference.<b>Methods</b>  Taking the actual case as the research object, combining the on-the-spot investigation, consulting the data, analyzing the data and so on, to study the operation mode and the current situation of the Internet drug distribution enterprises. <b>Results and Conclusions</b>  There are three main modes of Internet drug management: B2B, B2C and O2O, each of which has its own characteristics. It is suggested that the government should improve the policies and regulations and strengthen the supervision, and the enterprises should work together to promote the high-quality development of the Internet drug business.]]></description>
<pubDate>2022/2/23 16:42:52</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LIU Tianqi<sup>1</sup>, ZHAO Caihong<sup>2</sup>, CHEN Yujie<sup>2</sup>, TANG Xinghua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Tianqi<sup>1</sup>, ZHAO Caihong<sup>2</sup>, CHEN Yujie<sup>2</sup>, TANG Xinghua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201012&flag=1]]></guid><cfi:id>51</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research status and industry dynamics of Chinese medicine formula granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Chinese medicine formula granules are the product of the development of Chinese medicine decoction so far, which are easy to carry and take, accurate dose, easy to mix and store, stable and controllable quality, etc. The audience is becoming more and more extensive, the clinical prescription quantity is increasing year by year, and the market scale is constantly expanding. With the successive introduction of national policies, , it has attracted many enterprises to seize the window period after the introduction of policies and actively lay out the formula granules. This study recommended improving quality assurance measures, sinking sales of formula granules to grassroots communities and hospitals, expanding sales terminals, and actively exploring overseas markets to help Chinese medicine go abroad and shine on the world stage with the help of the international recognition of Chinese medicine formula granules particles.]]></description>
<pubDate>2022/12/12 13:59:59</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SHAO Chenglei<sup>1</sup>, LI Zhenpeng<sup>1</sup>, LU Jie<sup>1</sup>, ZONG Lei<sup>1</sup>, XU Jinkai<sup>1</sup>, SONG Chao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHAO Chenglei<sup>1</sup>, LI Zhenpeng<sup>1</sup>, LU Jie<sup>1</sup>, ZONG Lei<sup>1</sup>, XU Jinkai<sup>1</sup>, SONG Chao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211015&flag=1]]></guid><cfi:id>50</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Situation analysis of drug quality risk monitoring working mechanism construction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The situation of drug quality risk monitoring in Shandong province was analyzed to provide reference for further improving drug quality management. <b>Methods</b>   The work situation and measures of drug quality risk monitoring in Our province were analyzed, and the advantages, disadvantages, opportunities and challenges of the work mechanism construction of drug quality risk monitoring were analyzed by referring to SWOT. <b>Results and Conclusion</b>  Risk of drug quality monitoring work, as the important supplement of the conventional sampling inspection, give play to the role of the drug supervision and service enterprises, at the same time facing the favorable and unfavorable factors, the internal and external advice make full use of network intelligent supervision, optimizing the sampling work arrangements, strengthen business training, training expertise, perfecting the information disclosure, and pay attention to daily regulation,  We will constantly improve the working mechanism of drug quality risk monitoring, and comprehensively improve the effectiveness of drug supervision.]]></description>
<pubDate>2022/12/12 13:59:59</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHOU Weili<sup>1</sup>, ZHAO Yanxia<sup>1</sup>, SUN Tong<sup>1</sup>, WANG Kun<sup>1</sup>, HUA Fengbiao<sup>1</sup>, ZONG Fengyu<sup>2</sup>, CHENG Chunlei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Weili<sup>1</sup>, ZHAO Yanxia<sup>1</sup>, SUN Tong<sup>1</sup>, WANG Kun<sup>1</sup>, HUA Fengbiao<sup>1</sup>, ZONG Fengyu<sup>2</sup>, CHENG Chunlei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211016&flag=1]]></guid><cfi:id>49</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Current situation and problems of Shandong traditional Chinese medicine formula granules for the record and review]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, our country has accelerated the modernization of traditional Chinese medicine industry in an all-round way, by reforming the evaluation and approval system for traditional Chinese medicine (TCM). TCM formula granules is the inheritance of TCM integrated into the modern, which because of the characteristics of convenient and efficient development to a new way for clinical. The promulgation of “Opinions on the end of the pilot work of TCM formula granules” and “The national drug standards” by National Medical Products Administration, TCM formula granules entered the stage of vigorous development. This study summarized the development process of Chinese medicine formula granules, and the record and review in Shandong Province, analyzed the potential problems which might influence the safety, effective and quality control of TCM formula granules. Through the analysis, the meaning and key points of promoting TCM formula granules production and technical evaluation were proposed, which would be able to provide references for promoting the high-quality development of the Chinese medicine formula granules in the world.]]></description>
<pubDate>2022/11/11 10:33:32</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[HOU Jin, ZHANG Ping, SUN Mingwei, ZHAO Lanting, WANG Feng, YIN Ningning, WU Haijun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HOU Jin, ZHANG Ping, SUN Mingwei, ZHAO Lanting, WANG Feng, YIN Ningning, WU Haijun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210015&flag=1]]></guid><cfi:id>48</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[FDA胃肠道局部作用复杂仿制药的等效性评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:17</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[魏赫，李晓锋，李雪梅]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>魏赫，李晓锋，李雪梅</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309017&flag=1]]></guid><cfi:id>47</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[结合《药品管理法》对基层医疗机构药品安全监管分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:17</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[张敬涛，谢纪珍，赵彩虹，张娇，高华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张敬涛，谢纪珍，赵彩虹，张娇，高华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309018&flag=1]]></guid><cfi:id>46</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Suggestions for official Institutes for food and drug control to apply non-government science & technology rewards]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[According to historical evolution, official institutes for food and drug control have different specialties in research fields, priorities and basis. Non-governmental science & technology rewards have the characteristics of wide difficulty range and wide academic coverage, so they can play an important role as powerful supplements in the cultivation of major scientific research projects. In this article, it was described that the definition and current situation of domestic Non-governmental science & technology rewards. By analyzing of specialties, rewards projects/winners, and their institutes, non-government science & technology rewards which suit for official institutes for food and drug control were found and summarized. Therefore, conclusions and suggestions for applying non-governmental science & technology rewards were granted.]]></description>
<pubDate>2023/9/11 16:16:04</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[QIAN Chen, CHEN Jia]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIAN Chen, CHEN Jia</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308017&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and discussion of differences on the annex of GMP for manufacture of sterile medicinal products between China and the EU]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As high-risk products, the production process and quality control of sterile medicinal products are complex and special, and the published EU GMP Annex 1 has had a great impact on the quality management of sterile medicinal products worldwide. This paper analyzed and discussed the main differences between EU and China GMP Annex 1, to understand the international latest development trend and requirements of quality management of sterile medicinal products, grasp the current situation of quality management of sterile medicinal products in China, promote the improvement of the quality of sterile medicinal products in China. It provide reference for the revision of GMP Annex 1 and the quality improvement of sterile medicinal products manufacturers in China.]]></description>
<pubDate>2023/9/11 16:16:04</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[HU Jingfeng<sup>1</sup>, MING Yi<sup>1</sup>, WANG Jinzi<sup>2</sup>, SONG Kai<sup>1</sup>, FAN Hongyan<sup>1</sup>, FENG Qiaoqiao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Jingfeng<sup>1</sup>, MING Yi<sup>1</sup>, WANG Jinzi<sup>2</sup>, SONG Kai<sup>1</sup>, FAN Hongyan<sup>1</sup>, FENG Qiaoqiao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308018&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discuss the research and development about traditional Chinese medicine preparations in Shandong Province from the perspective of technical review]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine has unique advantages in the process of clinical treatment of diseases, among which the traditional Chinese medicine preparations in medical institutions are the wisdom crystallization of the clinical application of traditional Chinese medicine and the unique form of drug application in medical institutions. This paper discusses the factors that medical institutions should pay attention to in the research and development process of traditional Chinese medicine preparations, lists the common problems found in the technical review, and puts forward suggestions for medical institutions to do a good job in the registration and filing of traditional Chinese medicine preparations.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LIU Hui, MA Lingling, YIN Ningning, WANG Chunfang, WU Haijun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Hui, MA Lingling, YIN Ningning, WANG Chunfang, WU Haijun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307016&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the new model of talent training in the field of drug testing and research under the new situation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The quality and safety of drugs are closely related to people's life safety and health, and are serious political issues, basic livelihood issues, major economic issues, and rigorous technical issues. Providing strong technical support for drug supervision is an inevitable requirement for ensuring drug safety, and an important content for strengthening and innovating social management. After a new round of institutional reform, the drug inspection and testing system is not sound enough, and the problem of unclear functional positioning is prominent. This paper takes Shandong Institute for Food and Drug Control as an example to put forward feasible suggestions on how to build a high-quality and professional team of drug inspection talents for drug inspection and research, improve supervision ability and level, and ensure drug safety, in order to provide ideas for improving inspection and testing ability.]]></description>
<pubDate>2023/8/14 11:14:18</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHANG Yuanyuan, LYU Dengyi, JIANG Hui, WANG Lei, LENG Jiawei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yuanyuan, LYU Dengyi, JIANG Hui, WANG Lei, LENG Jiawei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202307017&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Summary and analysis of prescription preparations containing poppy husk in the 2020 edition of Chinese Pharmacopoeia (Part I)]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To expand the scope of TCM clinical drug use of prescription preparations containing poppy husk, and standardize the instructions and quality standards for the use of prescription preparations containing poppy husk.<b>Methods</b>  The formulations containing poppy husk collected in the 2020 edition of Chinese Pharmacopoeia (Part I) (hereinafter referred to as Part I) were summarized, focusing on the analysis of the dosage form, usage and dosage, usage taboo, inspection methods, the use of poppy husk in prescriptions and the processing methods of poppy husk in prescriptions, and suggestions were put forward to improve the level of clinical safe drug use. <b>Results</b>  According to the summary statistics and analysis of all varieties of 1607 formulations of traditional Chinese medicine prescription collected in the first part of Chinese Pharmacopoeia, there were 19 formulations of traditional Chinese medicine prescription containing poppy husk (including 1 extract of poppy husk), accounting for only 1.24% of all formulations of traditional Chinese medicine prescription in the first part of Chinese Pharmacopoeia. The basic research of prescription preparation containing poppy husk is weak, and there are some problems, such as few varieties of preparation, unclear dosage of individual varieties and non-standard expression of taboo in use.<b>Conclusion</b>  It is suggested to strengthen the basic research of prescription preparations containing poppy husk, expand the scope of clinical drug use, and strengthen post-marketing safety reevaluation, so as to achieve standardized use, improve the level of clinical rational use, and ensure the clinical drug safety of prescription preparations containing poppy husk.]]></description>
<pubDate>2023/7/25 13:23:06</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SONG Guangsheng<sup>1</sup>, SONG Wenqian<sup>2</sup>, LI Hongqiu<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Guangsheng<sup>1</sup>, SONG Wenqian<sup>2</sup>, LI Hongqiu<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306015&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and suggestions of national drug quality disclosure under the new situation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[National drug quality disclosure was an important way for the National Medical Products Administration to actively disclose the quality of drugs in accordance with laws and regulations. Against the backgrounds of the rapid development of new media, and the increased penalties for counterfeit and inferior drugs in the new version of the Drug Administration Law, the national drug quality disclosure was faced with many internal and external favorable and unfavorable factors. This paper analyzed strengths, weaknesses, opportunities, threats with the SWOT method, explored the main contradictions that the national drug quality disclosure should focus on under the new situation, and put forward suggestions from the aspects of strengthening drug supervision, policy publicity, public opinion monitoring, credit restoration, etc. for national drug quality disclosure to adapt to the new situation, in order to provide reference for relevant departments to make the best use of the situation, promote advantages and disadvantages, and implement precise policies.]]></description>
<pubDate>2023/5/25 8:59:34</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[WANG Chong<sup>1</sup>, LIU Wen<sup>1</sup>, ZHU Jiong<sup>1</sup>, HU Zengyao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Chong<sup>1</sup>, LIU Wen<sup>1</sup>, ZHU Jiong<sup>1</sup>, HU Zengyao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303015&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Interpretation of the newly revised “Quality management norms of drug use in Shandong Province”]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The revision of “Quality management norms of drug use in Shandong Province” (hereinafter  referred to as the "Norms") is another major measure of our province in promoting high-quality development and improving the system and mechanism in the field of drug use. This revision is not simply a change of articles and words, but a concrete embodiment of Shandong's development pattern of "walking in the forefront and creating in an all-round way", and the practice of the concept of "People's Drug Administration for the People", which has extremely important practical significance and far-reaching impact.This paper starts with the revision process and main change clauses of the "Norms"，explains the changes of the newly revised "Norms", expounds the main characteristics of the newly revised "Norms", analyzes its guiding significance in the actual implementation process, and further explores the important significance of the revision of the "Norms".]]></description>
<pubDate>2023/5/25 8:59:35</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Haifeng<sup>1</sup>, XIE Jizhen<sup>1</sup>, ZHANG Jingtao<sup>1</sup>, ZHAO Juhe<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Haifeng<sup>1</sup>, XIE Jizhen<sup>1</sup>, ZHANG Jingtao<sup>1</sup>, ZHAO Juhe<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202303016&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of Defective Items in Pharmaceutical Wholesale Enterprises Modification Inspection in Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to prevent and control the operation quality and safety risks of pharmaceutical wholesale enterprises, the data was collected from the defective items in pharmaceutical wholesale enterprises modification inspection from 2020 to 2021, in order to analyze the modification type and the defective items which were found in the on-site inspection, expert interviews to analyze the current status and problems of the quality management of pharmaceutical wholesale enterprises in Shandong Province, and put forward rationalized and professional countermeasures and suggestions for pharmaceutical wholesale enterprises in Shandong Province.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SHANG Jingying, ZHANG Jiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHANG Jingying, ZHANG Jiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302014&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Problems and Countermeasures in Pharmaceutical Cold Chain Logistics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the continual development of China's pharmaceutical market, the demand for cold chain logistics increases rapidly. To improve Pharmaceutical Cold Chain Logistics in China, we carried out retrieved literature, concerning the software and hardware facilities; the third party logistics；talent demand, present situation and existing problems of drug cold chain logistics were analysed and make appropriate recommendations. We hope to provide a reference for improving pharmaceutical cold chain drugs in China.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XU Luyuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Luyuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302015&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[仿制药评价新方法及其应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:46</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[陈思，黄哲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈思，黄哲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312017&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中印假劣药违法行为监管对比]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:46</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[肖妍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>肖妍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312018&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Quality risks analysis on the GMP compliance inspections requested by pharmaceutical enterprises in Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[By summarizing the requirements of laws and regulations for GMP compliance inspections, and statistically analyzing the various situations of GMP compliance inspections requested by pharmaceutical enterprises in Shandong province in 2021 and 2022, we find that the requests are relatively complex, and there are quality risks in quality management, production management, qualification and validation, data management, and other aspects. Pharmaceutical enterprises should pay much attention to the weaknesses in the quality management, fulfill their own duties as MAH holders, and continuously improve the GMP compliance level; Regulatory authorities should clarify key inspection points for different GMP compliance requests, and conduct on-site inspections scientifically and efficiently.]]></description>
<pubDate>2023/11/13 15:04:30</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[CAO Hongyan, ZHAO Jie, CHAI Fayong, ZHANG Jie, BAI Jianxue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Hongyan, ZHAO Jie, CHAI Fayong, ZHANG Jie, BAI Jianxue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310018&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of problems and reasons for cross-provincial record-keepingof traditional Chinese medicine dispensing granule]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the problems of cross-provincial record-keeping of Chinese medicine formula granule enterprises, and to provide reference for Chinese medicine formula granule enterprises to improve the quality of record-keeping data. <b>Methods</b> The cross-provincial record data submitted by the Pharmaceutical Business Application System of National Medical Products Administration were taken as the research object, the problems found in the record materials are analyzed and summarized by the method of summary and induction. <b>Results</b> the inadequacies and problems existed in the data integrity, production qualification, data of distribution enterprises, labels and test reports of the enterprises in Shandong Province The problems of application of national standard and provincial standard, validity period of record-keeping certificate and inheritance of record-keeping certificate between provinces. <b>Conclusion</b> the manufacturers of TCM formula granules need to study the laws, regulations and policies related to TCM formula granules, accurately grasp the requirements of cross-provincial sales records, and timely according to the changes of the national standard of TCM formula granules, to adjust the cross-provincial information submission, effectively carry out the main responsibility of quality assurance of traditional Chinese medicine formula particles, to ensure the authenticity, integrity and traceability of cross-provincial information.]]></description>
<pubDate>2024/10/9 16:27:02</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[GUO Chunbin<sup>1</sup>, LIU Dou<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Chunbin<sup>1</sup>, LIU Dou<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409018&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[新形势下药品生产智能风险预警模型的实践探索与思考]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[王君<sup>1</sup>，刘锜<sup>1</sup>，胡楠<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王君<sup>1</sup>，刘锜<sup>1</sup>，胡楠<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408018&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Visual Analysis of Continuing Education Research For Licensed Pharmacists in China from 2003 to 2023]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In this study, CNKI was used as data source to search the relevant publications of “Continuing education of licensed pharmacists”between 2003 and 2023,and visually analyzed the institution, author, keywords by CiteSpace software. The map of scientific knowledge showed the current research status and research hotspots in this field, providing references for further standardizing the continuing education of licensed pharmacists.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[WANG Jie<sup>1</sup>, ZHOU Ping<sup>1</sup>, PU Xiaofang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jie<sup>1</sup>, ZHOU Ping<sup>1</sup>, PU Xiaofang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407016&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of common problems in drug storage and transportation entrusted by drug wholesale enterprises in shandong province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  This paper analyzes the problems existing in the storage and distribution of drugs entrusted by drug wholesale enterprises in Shandong Province, and puts forward suggestions and countermeasures for scientific supervision of regulatory departments and continuous improvement of quality management level of enterprises. <b>Methods</b>  By using the methods of questionnaire, field investigation and analysis of inspection data, this paper analyzes the common problems of entrusted storage and distribution of drugs in drug wholesale enterprises in Shandong province.<b>Results</b>  There are certain quality risks in the entrusted storage and distribution of drugs by drug wholesale enterprises in Shandong Province, which mainly focus on the quality management of entrusted drugs, personnel and training, quality management system documents, computer management, drug transportation management and so on. <b>Conclusion</b>  The relevant departments of the state should strengthen the supervision and inspection, establish the modern drug logistics service system and standardize the social logistics management; In the process of drug consignment storage and distribution, enterprises should clarify the main responsibilities of both parties, attach importance to the quality system audit before consignment storage and distribution, and strengthen information management.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XIE Jizhen, SHANG Jingying, ZHANG Li, ZHANG Jiao, WANG Qun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Jizhen, SHANG Jingying, ZHANG Li, ZHANG Jiao, WANG Qun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407017&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Challenges and suggestions for the development of traditional marine Chinese medicine industry in China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The ocean contains abundant medicinal biological resources, which is called "blue medicine storehouse". Traditional marine Chinese medicine is an important part of traditional Chinese medicine in China, with a long clinical history and a good development prospect. In recent years, the overexploitation of marine resources, the reduction of marine biological resources caused by changes in the marine environment, and the lack of quality standards for marine traditional Chinese medicine have gradually become the bottleneck in the development of marine traditional Chinese medicine. Accordingly, this paper puts forward suggestions such as establishing a marine traditional Chinese medicine resource protection system, building a quality control standard system, and strengthening the construction of marine traditional Chinese medicine disciplines, in order to speed up the process of marine traditional Chinese medicine industrialization.]]></description>
<pubDate>2024/7/22 17:21:23</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LU Xianwen<sup>1,2</sup>, LI Wenjun<sup>1,2</sup>, TAI Song<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Xianwen<sup>1,2</sup>, LI Wenjun<sup>1,2</sup>, TAI Song<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406017&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The development countermeasure of traditional Chinese medicine industry in Fujian Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In the context of "Healthy China" strategy, the traditional Chinese medicine industry is of great significance for the overall economic and social development of China. In order to promote the level of the traditional Chinese medicine industry in Fujian Province, this article analyzes the current situation, comparative advantages, existing problems and their causes of the whole industry chain of traditional Chinese medicine industry in Fujian Province through literature search, and put forward the relevant countermeasures and suggestions, in order to provide a reference for the high-quality development of traditional Chinese medicine industry in Fujian Province.]]></description>
<pubDate>2024/7/22 17:21:23</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHENG Qing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Qing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406018&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Some considerations on the study of fat emulsion /amino acids /glucose injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fat emulsion/amino acids/glucose triple-chamber bag is an “all-in-one” parenteral nutrition solution supplied as a ready-to use formulation, which is intended for providing daily energy, essential fatty acids, amino acids and electrolytes to patients with mild to severe catabolism who are not candidates for gastrointestinal feeding, have an inadequate response to gastrointestinal feeding, or are diagnosed with gastrointestinal dysfunction. The three chambers of these products are completely isolated prior to use, while connect with each other after applying certain force during treatment. Such design can avoid the interaction between the components during sterilization and storage, increase the stability of the product, minimize the risk of secondarycontamination associated with clinical use, and improve the quality of life and prognosis of the patients. This article addresses several considerations for the pharmaceutical study on the generic drugs of triple-chamber bag of fat emulsion/amino acids/glucose based on the requirements in Chinese and international guidelines as well as our recent review experience, with the aim to provide instructions for subsequent research and development.]]></description>
<pubDate>2024/6/11 10:53:53</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHANG Xin, WANG Hongliang, WU Xiaofei, XU Zhenyu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xin, WANG Hongliang, WU Xiaofei, XU Zhenyu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405017&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Problems analysis and policy interpretation of changes to batch for chemical drug under the new regulations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  This paper can provide reference for relative parties to carry out batch change research, based on analyzing the problems, the status quo and interpretating the policy in the process of batch change.<b>Methods</b>  This paper deeply interpreted batch change of Technical Guideline for Making Post Approval Changes to Chemical Drug Products (Trial Implementation), and summarized the common problems and the status quo in the batch change of listed chemical drug in Shandong province. <b>Results</b>  As the batch change added affter the implementation of Technical Guideline for Making Post Approval Changes to Chemical Drug Products (Trial Implementation), batch change is usually relative to many aspects of the production process, such as equipment, process, parameters, solvent ratio and so on. Although the post-approval chemical drugs pass rate of the batch change is increased, but the understanding of the regulatory documents in applicants still needs to be improved. <b>Conclusion</b>  The implementation of the New Regulations provid legal support for the application of new technology and new equipment, expanding production capacity, improving competitive advantage. As the main body of listed drug change researches, marketing authorization holders should pay more attention to associated changes in batch change, conduct change research more scientifically.]]></description>
<pubDate>2024/6/11 10:53:53</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHOU Chong<sup>1</sup>, LIU Juntian<sup>1</sup>, XIE Jizhen<sup>1</sup>, XU Xiaojuan<sup>1</sup>, WU Haijun<sup>1</sup>, MA Chao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Chong<sup>1</sup>, LIU Juntian<sup>1</sup>, XIE Jizhen<sup>1</sup>, XU Xiaojuan<sup>1</sup>, WU Haijun<sup>1</sup>, MA Chao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405018&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the development and evaluation of new drugs of oral soluble film]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Films refer to the film-like preparation made by processing the raw material and the appropriate film-forming material. Oral soluble film refers to the film that dissolves rapidly in the mouth.The characteristics of the oral soluble film include accurate dose, easy to carry, and improving the compliance of patients with specific indications. Based on the requirements of registration regulations and approval of oral soluble films at home and abroad in recent years, the evaluation of oral soluble films were put forward in terms of development, formulation, manufacturing process and quality research and control. The application strategy and path should be rationally selected after comprehensive evaluation. During formulation and process development, focus on the key factors affecting product quality according to the characteristics of dosage forms, and conduct targeted quality research and control. These discussions are expected to guide the development and evaluation of oral soluble films, and promote the approval and marketing of high-quality oral soluble film new drugs with clinical needs.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[WANG Lu, HU Yanchen, WANG Yamin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Lu, HU Yanchen, WANG Yamin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403017&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Defective items and countermeasures of wholesale enterprises specialized in TCM decoction pieces in Shandong province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The countermeasures and suggestions were put forward in order to provide reference for the guarantee of TCM quality in Shandong Province, through the analysis of the licensing situation and the problems found in the on-site inspection of the wholesale enterprises specialized in TCM decoction pieces in Shandong Province. <b>Methods</b>  Statistics were made on defective items of licensing inspection of the wholesale enterprises specialized in TCM decoction pieces in Shandong Province from 2020 to 2022, the existing problems were analyzed to put forward countermeasures. <b>Results</b>  The common problems found in the licensing on-site inspection mainly focus on quality management system documents, organization and quality management responsibilities, personnel and training, and facilities and equipment. <b>Conclusion</b>  Enterprises should strictly implement the main responsibilities and improve the quality management system, pay attention to internal audit work and improve the effectiveness of training，should transform and upgrade to improve industrial concentration. The supervision department should strengthen supervision, improve the on-site inspection ability of TCM inspectors, and speed up the construction of professional and specialized TCM inspectors.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XING Qian<sup>1</sup>, XIE Jizhen<sup>1</sup>, ZHANG Jingtao<sup>1</sup>, CHEN Yujie<sup>1</sup>, YANG Chengyong<sup>1</sup>, WANG Hongwei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XING Qian<sup>1</sup>, XIE Jizhen<sup>1</sup>, ZHANG Jingtao<sup>1</sup>, CHEN Yujie<sup>1</sup>, YANG Chengyong<sup>1</sup>, WANG Hongwei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403018&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Some considerations on the study of nutritional fat emulsions]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Nutritional fat emulsions are usually oil-in-water emulsions prepared by emulsifying oils extracted from animals and plants as the oil phase, phospholipids as emulsifiers, supplemented with isotonic agents and water for injection. As an ideal energy supply substance for parenteral nutrition, nutritional fat emulsions can provide essential fatty acids and maintain cell structure and functions. Thus, quality control of nutritional fat emulsions requires further improvements considering the complex composition of their APIs and high requirements for production process. In order to provide guidance for future research and development, this article addresses some research considerations based on the characteristics of nutritional fat emulsions, drug evaluation experience, and current domestic and foreign regulatory requirements.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHANG Xin, WU Xiaofei, WANG Hongliang, BAI Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xin, WU Xiaofei, WANG Hongliang, BAI Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402017&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A comparative study on the professional qualification system of licensed pharmacists and the legal professional qualification system in China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to improve the professional qualification system of licensed pharmacists and promote the development of licensed pharmacists.This paper compares the current professional qualification system and legal qualification system of licensed pharmacists in China from the aspects of system system, examination management, registration (practice) management.It is found that China's licensed pharmacists professional qualification system and legal professional qualification system have established a system and management such as qualification examination, licensing, supervision and management, education and training, and the development of the team has made great progress.There are differences in system construction, policy implementation, examination management, licensing management, supervision and inspection.In view of the development bottleneck of licensed pharmacist system, the author draws on the experience of legal professional qualification system, it proposed to improve the legal system with the core of "the posts that should be equipped with licensed pharmacists", carry out strategic research, give full play to the role of qualification system as a "reservoir", implement the policy of "six stability", "six guarantee" and "separate marking", take multiple measures to promote the development of the team, establish an assessment management system, continue to carry out positive publicity, strengthen competency training, and improve the quality and ability.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHOU Yue, MA Xiangjun, XIE Guoliang, LI Chaohui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Yue, MA Xiangjun, XIE Guoliang, LI Chaohui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402018&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A comparative study of risk-based drug inspection between NMPA and US FDA]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to continue to explore and improve the working methods of risk-based drug inspection in China, this paper describes the institutions, regulatory documents and implementation procedures related to drug inspection in the United States, and analyzes the shortcomings in the implementation of risk-based drug registration inspection in China through comparison. Some specific suggestions are put forward to promote the more scientific and standardized risk-based drug registration inspection in our country.]]></description>
<pubDate>2024/2/26 16:18:01</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Yuan, ZHOU Gang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yuan, ZHOU Gang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401017&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Current Status and Problems in the Research of Traditional Chinese Medicine Formula Granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As an innovative form of traditional Chinese medicine, Chinese medicine formula granules have accurate clinical efficacy, easy to use, safe medication, and great market potential in traditional Chinese medicine. With the successive introduction of national and provincial quality standards for traditional Chinese medicine formula granules, formula granules have been rapidly promoted and applied, and their industrial development has also opened a new stage. However, so far, the formulation of quality standards for Chinese medicine formula granules and the supervision of sales and production are not perfect, and extensive and in-depth discussion and research are still needed. Therefore, this paper reviews the relevant contents of the research on the quality standards of traditional Chinese medicine formula granules, thinks about the problems found in the application of formula granules, and makes suggestions based on the actual situation, so as to provide reference for improving the quality control of traditional Chinese medicine formula granules, improving the rationality of their clinical application, and guiding the healthy development of the traditional Chinese medicine formula granules industry.]]></description>
<pubDate>2024/2/26 16:18:01</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Gaoyan<sup>1</sup>, YANG Yidi<sup>2</sup>, QU Fanna<sup>2</sup>, LIU Qibin<sup>1</sup>, BI Xueyan<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Gaoyan<sup>1</sup>, YANG Yidi<sup>2</sup>, QU Fanna<sup>2</sup>, LIU Qibin<sup>1</sup>, BI Xueyan<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401018&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Risk Analysis and Countermeasures on Responsibility- based GMP Compliance Inspection of High-Risk Drug Manufacturing Enterprises in Anhui Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to ensure continued adherence of high-risk drug manufacturing enterprises to GMP, a statistical analysis was performed on the deficiencies identified during the responsibility-based GMP compliance inspections conducted in Anhui Province from 2021 to 2023. A total of 1 408 inspection defects were summarized, including 7 serious defects, 88 major defects and 1 313 general defects, which were mainly in the aspects of quality control and quality assurance, document management, sterile drug appendices, etc. High-risk drugs manufacturing enterprises should implement the main responsibility, strengthen contamination control strategy, establish long-term training mechanism, strictly manage suppliers, improve confirmation and verification and enhance product quality review analysis to continuously improve high-risk drugs quality and safety.]]></description>
<pubDate>2024/11/18 11:12:33</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[RUI Xue, YE Liuping, HU Shigao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>RUI Xue, YE Liuping, HU Shigao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202410018&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Inspection and risk analysis of post-market changes(change of production site ) of drugs--Taking Shandong Provinee as an example]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To understand the current situation of quality management regarding post-market changes (changes in production sites) of drugs in Shandong Province, identify the common defect issues in the inspection of production site changes, explore the main risk points existing in the on-site inspection of post-market changes, and provide references for enterprises to implement post-market changes more standardized. <b>Methods</b>  Summarize the requirements of laws and regulations for post-market changes (changes in production sites) of drugs, and conduct a statistical analysis of the inspection defects of production site changes of drug enterprises in Shandong Province in 2024. <b>Results</b>  The inspection defects of post-market changes (changes in production sites) of drugs mainly concentrate on aspects such as document management, quality control and quality assurance, confirmation and verification, institutions and personnel. <b>Conclusion</b>  It is recommended that enterprises should pay special attention to the above-mentioned defects when implementing post-market changes (changes in production sites), continuously improve and enhance them to ensure the continuous and effective operation of the quality management system.]]></description>
<pubDate>2025/10/14 16:33:21</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[HAN Ying, BAI Jianxue, LIU Rong, CHAI Fayong, DUAN Shutao, CAO Hongyan, ZHANG Jie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Ying, BAI Jianxue, LIU Rong, CHAI Fayong, DUAN Shutao, CAO Hongyan, ZHANG Jie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509017&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on communication mechanism oriented by quality and efficiency in drug registration testing]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[To explore the establishment of a communication and exchange mechanism involving drug evaluation agencies, applicants, and drug inspection agencies in the process of drug registration testing, in order to improve the quality and efficiency of drug registration testing. From the perspective of project management, clarify the responsibilities of drug registration testing participants, and analyze the influencing factors of registration testing quality and efficiency. Propose the content of the communication mechanism from four aspects: communication initiation principles, communication methods, application of communication results, and evaluation of communication effectiveness. Establish a communication and exchange mechanism involving drug review agencies, applicants, and inspection agencies to timely coordinate and solve common and individual problems in drug registration testing. The mechanism is better leverage the technical support role of registration testing in drug review.]]></description>
<pubDate>2025/5/9 9:16:55</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHONG Xuanwei, XUE Jing, TIAN Xuebo, ZHANG Weimin, WANG Shan, LI Ying, JIANG Yingjun, LI Lulu, LIU Wenting, ZHAO Fanbo, HUANG Baobin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Xuanwei, XUE Jing, TIAN Xuebo, ZHANG Weimin, WANG Shan, LI Ying, JIANG Yingjun, LI Lulu, LIU Wenting, ZHAO Fanbo, HUANG Baobin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504017&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the innovation of working mechanism of registration and inspection for overseas production of chemical drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To carry out scientific research on drug regulation, innovative working mechanism for the completion of high-quality registration and inspection of overseas production of chemical drugs. <b>Methods</b>  According to the information review, standard review, standard audit three stages, sorting and summarizing the common problems highlighted in the registration and inspection work, to adapt to the “Administrative Measures for Drug Registration” work requirements, put forward an innovative working mechanism for practical exploration, comparison of working mechanisms before and after the operation of the variety of registration and inspection time and efficiency.<b>Results</b>  Compared with the new “Administrative Measures for Drug Registration” before the implementation of the new mechanism, the new mechanism after the operation of the data review phase of the data received from 11.2 natural days to shorten the time to 1.4 days, 62% shorter than the standard review stage, the standard review stage audit waiting time from 20.5 working days to 1 day. <b>Conclusion</b>  By carrying out parallel review of information, optimize the allocation of species, the report that is the review of innovative initiatives to establish a new working mechanism, effectively improve the efficiency of the registration and inspection of overseas production of chemical drugs, streamline the procedures and steps to shorten the test time, has become an important cornerstone of the high-quality completion of the registration and inspection of overseas production of chemical drugs, can be extended to the full range of innovative working mechanisms to promote the registration and inspection of innovative medicines. The innovative working mechanism can be extended and applied to the registration and inspection of all varieties, thus promoting the accelerated listing of innovative drugs.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Wenlong, WANG Xuelei, TAN Liyuan, WEI Jingjing, WU Zhaoyang, YAO Shangchen, HUANG Haiwei, SUN Huimin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Wenlong, WANG Xuelei, TAN Liyuan, WEI Jingjing, WU Zhaoyang, YAO Shangchen, HUANG Haiwei, SUN Huimin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503014&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploration and analysis of common problems and countermeasures in
the change of production process of listed Chinese traditional medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Objective  To understand the current status and urgent issues to be solved in the change of production process of listed traditional Chinese medicine，providing references for scientific and standardized research on the change of listed traditional Chinese medicine conducted by holders and for the technical review and supervision by regulatory authorities. Methods  By sorting out and summarizing the difficult problems in the process of changing the production process of listed traditional Chinese medicine in Shandong Province, analyzing the possible risks and problems, and in view of the scientific and standardized Chinese medicine production process changes and reasonable to solve the problem, discusses the effective control of risks and advice were put forward. Results  The results of this study indicate that holders of drug marketing authorization have problems such as insufficient verification of change research, unreasonable classification of changes, and deficiencies in research data during the process of traditional Chinese medicine production process changes. Conclusion  This study puts forward reasonable suggestions from strengthening the management of TCM production process change.The holder of drug marketing authorization should fully fulfill its main responsibilities,Strengthen the construction of drug quality management system, leverage advanced production technology, and continuously improve the level of product quality control,reasonably carry out changes in the production process of traditional Chinese medicine preparations;Drug regulatory departments can strengthen regulatory services by adopting publicity and implementation, training, case sharing and other ways to improve the business ability of regulatory personnel.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[MA Lingling, ZHAO Lanting, LIU Hui, SUN Mingwei, LU Xueming, WANG Chunfang, YANG Yingying, YIN Ningning, WU Haijun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Lingling, ZHAO Lanting, LIU Hui, SUN Mingwei, LU Xueming, WANG Chunfang, YANG Yingying, YIN Ningning, WU Haijun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503015&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of differences and implementation suggestions between the appendix of pharmaceutical excipients and the good manufacturing practice for pharmaceutical excipients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pharmaceutical excipients play a crucial role in the effectiveness of drugs, and the National Medical Products Administration's newly released "Good Manufacturing Practice for Drugs (Revised in 2010)" appendix on pharmaceutical excipients has a significant impact on promoting the production quality of pharmaceutical excipients. To understand the new requirements for the production of pharmaceutical excipients in the new appendix, provide reference for the quality improvement of pharmaceutical excipient production enterprises, and promote the improvement of excipient quality management level. This article compared and analyzed the "Appendix to Medicinal Excipients" with the "Quality Management Standards for Medicinal Excipients Production" released in 2006, and refers to the current requirements of drug GMP to provide implementation suggestions for the new version of the "Appendix to Medicinal Excipients" for excipient production enterprises in China.]]></description>
<pubDate>2025/11/10 14:18:31</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[WANG Xin<sup>1</sup>, WU Fuzhao<sup>2</sup>, BAI Jianxue<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xin<sup>1</sup>, WU Fuzhao<sup>2</sup>, BAI Jianxue<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202510016&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative analysis and application of pharmaceutical manufacturing licensing systems in Australia and China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[At present, China＇s pharmaceutical industry is gradually gaining prominence on the international stage. As a member of PIC/S, obtaining GMP certification from Australia's TGA grants access to pharmaceutical markets in over 50 countries, including all PIC/S member states such as those in the EU. This article outlines the organizational structure of the Therapeutic Goods Administration (TGA) and its pharmaceutical manufacturing licensing procedures. It further compares the core logical differences between domestic pharmaceutical manufacturing licensing systems and Australia＇s TGA certification framework, identifies the pain points encountered by Chinese pharmaceutical enterprises during overseas Good Manufacturing Practice (GMP) certification applications, and proposes targeted solutions. The study aims to provide practical references for domestic pharmaceutical manufacturers to optimize their industrial layout, simplify the Australian GMP compliance process, and facilitate smooth access to the international pharmaceutical market.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHAO Jie, CHAI Fayong, SHI Yan, XING Xiaomin, FANG Juanjuan, CAO Hongyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Jie, CHAI Fayong, SHI Yan, XING Xiaomin, FANG Juanjuan, CAO Hongyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609018&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于FMEA的除菌过滤系统风险研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/9/15 9:10:52</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[孔庆斌<sup>1</sup>，韩雨<sup>2</sup>，宋凯<sup>3</sup>，蔡子洋<sup>4</sup>，张蕾<sup>5</sup>，马岩松<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孔庆斌<sup>1</sup>，韩雨<sup>2</sup>，宋凯<sup>3</sup>，蔡子洋<sup>4</sup>，张蕾<sup>5</sup>，马岩松<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202608017&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison study for the re-inspection/re-examination procedures of drugs, medical devices, and cosmetics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[A systematic comparison was conducted on the regulatory similarities and differences in the re-inspection/re-examination procedures among drugs, medical devices, and cosmetics. It was found that inconsistencies existed in the current regulations regarding core procedures such as the accepting institutions and inspection time limits. Meanwhile, common problems were identified, including non-unified sample sealing management, inconsistent implementation of report delivery time limits, unclear legal validity of electronic inspection reports, prominent issues of duplicate applications by multiple parties, inconsistent provisions on the independence of re-inspection/re-examination institutions, and the lack of termination mechanisms when applications could not be accepted, all of which affected the efficiency and impartiality of the remedy process. To enhance regulatory credibility and the protection of applicants' rights, it was suggested that a standardized and consistent procedural framework should be established, the legal validity of electronic reports should be clarified, unified standards for delivery confirmation and multi-party application rules should be established, differentiated treatment of re-inspection/re-examination and objections should be explored, and communication mechanisms and information platform construction should be improved.]]></description>
<pubDate>2026/8/12 14:14:04</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XUE Jing, HUANG Baobin, ZHONG Weixuan, WANG Shan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUE Jing, HUANG Baobin, ZHONG Weixuan, WANG Shan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607017&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative analysis of multi-warehouse collaboration policy of drug business in some provinces of China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide policy references for drug regulatory authorities and drug distribution enterprises by analyzing the implementation documents of multi-warehouse collaboration policies in 14 provinces including Beijing, Shanghai, Guangdong, Liaoning, Yunnan, and Xinjiang, thereby promoting the high-quality development of the industry. <b>Methods</b>  An analytical framework was constructed with three core aspects and nine dimensions, including the release time of policy documents, licensing requirements (application subjects, licensing methods, collaboration scope, and collaboration methods), and collaboration responsibilities (organizational guarantees, quality system construction, computer system requirements, and process optimization). The policy documents of various provinces were compared to extract commonalities and differences, analyze regulatory difficulties, and propose optimization suggestions.<b>Results</b>  Most provinces across the country have promoted multi-warehouse collaboration through policy documents, notices, or draft opinions. Common rules have been formed in terms of adhering to the bottom line of drug quality and safety, clarifying the responsibilities of all parties, and controlling key risk links. However, there are regional differences in aspects such as the qualifications of participating entities, collaboration scope, and instruction execution models. Moreover, there is a lack of a unified policy framework and clear legal basis at the national level.<b>Conclusion</b>  While the multi-warehouse collaboration model in drug distribution has stimulated the vitality of the drug circulation market, its continuous development is constrained by factors such as regional rule differences and policy fragmentation. Through multi-angle comparative analysis of the multi-warehouse collaboration policy documents of various provinces, suggestions that are conducive to the standardized and healthy development of the industry are proposed to support the scientific policy-making of regulatory authorities.]]></description>
<pubDate>2026/8/12 14:14:04</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Haifeng<sup>1</sup>, ZHAO Caihong<sup>1</sup>, LIN Xiaoming<sup>1</sup>, CHEN Gang<sup>2</sup>, RAN Daqiang<sup>1</sup>, SUN Bing<sup>3</sup>, XUE Runpu<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Haifeng<sup>1</sup>, ZHAO Caihong<sup>1</sup>, LIN Xiaoming<sup>1</sup>, CHEN Gang<sup>2</sup>, RAN Daqiang<sup>1</sup>, SUN Bing<sup>3</sup>, XUE Runpu<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202607018&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative study on the drug import inspection systems between China and the United States]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> A systematic comparison was made between the drug import inspection systems of China and the United States to provide a reference for the optimization of China's system. <b>Methods</b>  A comparative analysis was conducted from four dimensions: institutional framework, port procedures, technical specifications and enforcement tools. <b>Results</b>  It was found that both countries had established hierarchical management mechanisms with risk control as the core, and the port procedures were basically similar. The main differences were manifested in the mandatory nature of pharmacopoeia and the sophistication of enforcement tools. Regarding special categories, imported orphan drugs were permitted for clinical use prior to formal market authorization in China, while pre-market incentives were emphasized in the United States; for biological products, a more extensive batch release system was enforced in China, whereas process control was primarily relied upon in the United States; and for Chinese medicinal materials and Chinese medicines, batch-by-batch inspection was conducted in China, while dietary supplements were regulated as they are in the United States. <b>Conclusion</b> Overall, a high degree of similarity was observed between the systems of China and the United States. Continuous improvements could be made by China in joining PIC/S, developing intelligent interception tools, optimizing customs clearance for orphan drugs, and strengthening post-market whole-chain supervision, so that a better balance between the safety and efficiency of drug imports could be achieved.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[XUE Jing, ZHONG Xuanwei, WANG Shan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUE Jing, ZHONG Xuanwei, WANG Shan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606016&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploration of "Three-in-One" collaborative inspection model for pharmaceuticals]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore a novel model for collaborative drug regulatory inspections, with the aim of enhancing regulatory efficiency, optimizing the allocation of inspection resources, alleviating the burden on enterprises, and providing practical references for improving the drug regulatory system and promoting high-quality development of the pharmaceutical industry.<b>Methods</b>  This study reviews the practical implementation of the "tripartite integrated inspection" model in the field of post-approval change filings in Shandong Province since February 2023. Focusing on the optimization of inspection resources and the enhancement of inspector competencies as core evaluation indicators, it systematically summarizes the implementation experience of this model in terms of mechanism establishment, process innovation, and team development.<b>Results and Conclusion</b>  Through key measures such as institutional refinement, process optimization, and comprehensive risk management throughout the inspection cycle, the "tripartite integrated inspection" model has effectively improved the efficiency of inspection resource allocation and significantly strengthened the comprehensive capabilities of the inspection team. This model provides a replicable practical pathway for the collaborative development of drug regulation and holds significant practical value for enhancing the quality and effectiveness of drug oversight and empowering the high-quality development of the industry.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SUN Limin, ZENG Kun, ZHANG Zhen, MU Yuejing, ZHAO Zhenzhen, HAN Ying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Limin, ZENG Kun, ZHANG Zhen, MU Yuejing, ZHAO Zhenzhen, HAN Ying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606017&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Considerations on improving the consistency and standardization of procedures and technical requirements for drug registration testing]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore measures to enhance the consistency and standardization of drug registration testing nationwide, improve collaboration among drug testing institutions, and strengthen the supporting role of drug registration testing in the evaluation process, thereby better serving the high-quality development of the pharmaceutical industry.<b>Methods</b>  The regulatory system for drug registration testing was reviewed, combined with the quality management system requirements for drug testing institutions in China. The challenges in consistency and standardization of drug registration testing were analyzed, and suggestions for improvement were proposed. <b>Results and Conclusion</b>  Challenges remain in the consistency and standardization of drug registration testing in terms of procedures, documentation, technical requirements for standard review, information technology infrastructure, and implementation of the newly revised procedures. Recommendations include improving the management system for drug registration testing, developing technical guidelines, enhancing IT and intelligent application, standardizing guidance services for applicants, and strengthening inter-departmental communication and coordination.]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[ZHONG Xuanwei, HUANG Baobin, LIU Wenting, WANG Shan, LI Lulu, XUE Jing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Xuanwei, HUANG Baobin, LIU Wenting, WANG Shan, LI Lulu, XUE Jing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605016&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative study on cleaning validation guidelines in domestic and international pharmaceutical production]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cleaning validation is a critical measure to ensure the cleanliness of production equipment and environments during pharmaceutical manufacturing, preventing cross-contamination. Its primary objective is to scientifically verify the effectiveness of cleaning procedures, guaranteeing that the produced drugs meet quality standards. Both domestic and international Good Manufacturing Practices (GMP) include requirements for cleaning validation; however, regulatory expectations vary across different countries and regions. These differences may stem from divergent guidelines and specific regulations set by national pharmaceutical regulatory agencies. A comparative study can help pharmaceutical manufacturers better understand and comply with regulatory requirements in different markets, thereby enhancing their global competitiveness.]]></description>
<pubDate>2026/5/12 0:00:00</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[CAO Hongyan<sup>1</sup>, ZHAO Jie<sup>1</sup>, HU Jingfeng<sup>1</sup>, LI Wuchao<sup>2</sup>, HAN Ying<sup>1</sup>, LIU Yong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Hongyan<sup>1</sup>, ZHAO Jie<sup>1</sup>, HU Jingfeng<sup>1</sup>, LI Wuchao<sup>2</sup>, HAN Ying<sup>1</sup>, LIU Yong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202604017&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on the efficiency evaluation of drug risk monitoring and sampling inspection based on risk identification]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Abstract</b>:<b>Objective</b>  To evaluate the risk identification efficiency of risk monitoring sampling and provide reference for improving the quality and efficiency of drug quality sampling.<b>Methods<b/>  Data drug sampling inspections during 2021—2023 were sorted out to analyze and evaluate the risk detection rates of evaluation sampling, supervisory sampling, and risk monitoring sampling, as well as risk issues identified through exploratory research in risk monitoring and enterprise confirmation status.<b>Results</b>  The risk issue detection rate of risk monitoring sampling was 1.39%, significantly higher than that of supervisory sampling (0.34%) and evaluation sampling (0.02%), with traditional Chinese patent medicines having the highest risk issue detection rate. The reproducibility rate of enterprise re-test results for risk issues was 78.1%, the number of enterprise confirmations increased annually, the average verification rate was 75.2%, and enterprises' recognition rate of exploratory research results increased year by year.<b>Conclusion</b>  Risk monitoring sampling demonstrates high risk identification efficiency, enabling early detection, prevention, and elimination of potential drug risks, making up for the shortcomings of routine sampling and serving as an effective supplement to the quality sampling system.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[SUN Jing, WAMG Xiaobing, GUO Dongxiao, WANG Guojin, LIU Wenkun, CHENG Chunlei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Jing, WAMG Xiaobing, GUO Dongxiao, WANG Guojin, LIU Wenkun, CHENG Chunlei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603015&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Scenario-based design and implementation of quality control function of computer system in pharmaceutical enterprises]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Abstract</b>:Along with the development of our country's pharmaceutical logistics industry informationization process, the application means of pharmaceutical management enterprise informationization are rich and varied. In the appendices, the requirements of the computer system and the quality control function of the computer system are clearly defined in the code for the quality management of drug operation (hereinafter referred to as GSP) , the specific control function of some enterprises is not yet clear, the application of individual functions did not meet the requirements. Based on the relevant literature, this paper systematically summarized the relevant contents in GSP, the Guiding Principles for On-site Inspection of Drug Quality Management Norms and GSP Appendix 2: Computer System for Drug Enterprises, according to the running characteristics of the computer system, the quality control measures of the computer system in drug purchase, storage, sale and transportation are analyzed by using the scene thinking and combining with the actual inspection work, to define the functions of judgment, identification and control that should be set up in each scene in the system, so as to provide useful reference for drug inspection departments and compliance basis for information construction of drug distribution enterprises, to promote the development of high-quality medical logistics industry information construction.]]></description>
<pubDate>2026/4/14 10:27:27</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LIN Xiaoming, LI Haifeng, NIE Jiaodong, ZHAO Caihong, CHEN Yujie, SHANG Jingying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Xiaoming, LI Haifeng, NIE Jiaodong, ZHAO Caihong, CHEN Yujie, SHANG Jingying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202603016&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the problems in the development of preparations in medical institutions and suggestions for countermeasures]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Through the analysis of the research data on the preparations of medical institutions in Shandong Province, combined with the relevant literature on the preparations of medical institutions in some provinces and cities across the country, this paper sorts out the problems in the development of medical institution preparations in China and puts forward relevant suggestions. The statistical results show that as of 2023, there were 132 medical institutions in Shandong Province holding preparation numbers, 109 medical institutions holding Medical Institution Preparation Licenses, and 2 391 preparations. All these figures exhibited a significant decreasing trend compared with those in 2014. The reasons for this situation include talent - related factors, hardware conditions, quality system, management system, etc. It is recommended to improve the development environment of the medical institution preparation industry from the perspectives of internal management and external policies, explore innovative cooperation models, expand the market space, establish a sound scientific research cooperation platform, and promote the high - quality development of medical institution preparations.]]></description>
<pubDate>2026/3/17 14:12:45</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[LI Qiang<sup>1</sup>, DUAN Shutao<sup>1</sup>, ZHANG Hui<sup>2</sup>, LYU Zheng<sup>2</sup>, DAI Yanpeng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Qiang<sup>1</sup>, DUAN Shutao<sup>1</sup>, ZHANG Hui<sup>2</sup>, LYU Zheng<sup>2</sup>, DAI Yanpeng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202602018&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[执业药师配备与履职现状实地调查]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:26</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[周玥<sup>1</sup>，吴一楠<sup>1</sup>，王梦璐<sup>1</sup>，王元明<sup>2</sup>，山亚男<sup>2</sup>，郝国祥<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>周玥<sup>1</sup>，吴一楠<sup>1</sup>，王梦璐<sup>1</sup>，王元明<sup>2</sup>，山亚男<sup>2</sup>，郝国祥<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610014&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[山东省执业药师继续教育培训现状与分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2026/11/17 13:22:26</pubDate>
<category><![CDATA[Pharmaceutical Management]]></category>
<author><![CDATA[赵彩虹<sup>1</sup>，薛润璞<sup>2</sup>，山亚男<sup>3</sup>，侯玉磊<sup>1</sup>，栾振兴<sup>4</sup>，张敬涛<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵彩虹<sup>1</sup>，薛润璞<sup>2</sup>，山亚男<sup>3</sup>，侯玉磊<sup>1</sup>，栾振兴<sup>4</sup>，张敬涛<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202610015&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>